Innate Pharma To Present New Clinical Data For Lacutamab And SAR443579/IPH6101 At American Society Of Hematology 2023
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma will present new clinical data for Lacutamab and SAR443579/IPH6101 at the American Society of Hematology 2023. This could potentially impact the company's stock performance depending on the results of the presentation.
November 03, 2023 | 6:29 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Innate Pharma's stock performance could be influenced by the presentation of new clinical data for Lacutamab and SAR443579/IPH6101 at the American Society of Hematology 2023.
The presentation of new clinical data is a significant event for pharmaceutical companies like Innate Pharma. Depending on the results, it could either boost investor confidence, leading to a potential increase in stock price, or it could have the opposite effect if the results are not favorable. Therefore, the impact on the stock price is uncertain at this point.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100